Premium
Favourable prognostic value of antibodies anti‐HSP20 in patients with cystic echinococcosis: a differential immunoproteomic approach
Author(s) -
VACIRCA D.,
PERDICCHIO M.,
CAMPISI E.,
DELUNARDO F.,
ORTONA E.,
MARGUTTI P.,
TEGGI A.,
GOTTSTEIN B.,
SIRACUSANO A.
Publication year - 2011
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/j.1365-3024.2010.01264.x
Subject(s) - antibody , disease , cystic echinococcosis , immunology , antigen , biomarker , differential diagnosis , hsp70 , heat shock protein , echinococcosis , medicine , biology , gastroenterology , pathology , biochemistry , gene
Summary Seeking biomarkers reflecting disease development in cystic echinococcosis (CE), we used a proteomic approach linked to immunological characterisation for the identification of respective antigens. Two‐dimensional gel electrophoresis (2‐DE) of sheep hydatid fluid, followed by immunoblot analysis (IB) with sera from patients with distinct phases of disease, enabled us to identify by mass spectrometry heat shock protein 20 (HSP20) as a potential marker of active CE. Using IB, antibodies specific to the 34 kDa band of HSP20 were detected in sera from 61/95 (64%) patients with CE, but not in sera from healthy subjects. IB revealed anti‐HSP20 antibodies in a higher percentage of sera from patients with active disease than in sera from patients with inactive disease (81 vs. 24%; P = 10 −4 ). These primary results were confirmed in a long‐term follow‐up study after pharmacological and surgical treatment. Herewith anti‐HSP20 antibody levels significantly decreased over the course of treatment in sera from patients with cured disease, relative to sera from patients with progressive disease ( P = 0·017). Thus, during CE, a comprehensive strategy of proteomic identification combined with immunological validation represents a promising approach for the identification of biomarkers useful for the prognostic assessment of treatment of CE patients.